Review

Cell-Based Mechanosensation, Epigenetics, and Non-Coding RNAs in Progression of Cardiac Fibrosis

Silvia Ferrari 1,2 and Maurizio Pesce 1,*

1 Unità di Ingegneria Tissutale Cardiovascolare, Centro Cardiologico Monzino, IRCCS, Milan 20138, Italy; silvia.ferrari@ccfm.it
2 PhD Program in Translational Medicine, Università degli studi di Pavia, Pavia 27100, Italy
* Correspondence: maurizio.pesce@ccfm.it; Tel.: +39 58-002-019

Received: 29 November 2019; Accepted: 15 December 2019; Published: 19 December 2019

Abstract: The heart is par excellence the ‘in-motion’ organ in the human body. Compelling evidence shows that, besides generating forces to ensure continuous blood supply (e.g., myocardial contractility) or withstanding passive forces generated by flow (e.g., shear stress on endocardium, myocardial wall strain, and compression strain at the level of cardiac valves), cells resident in the heart respond to mechanical cues with the activation of mechanically dependent molecular pathways. Cardiac stromal cells, most commonly named cardiac fibroblasts, are central in the pathologic evolution of the cardiovascular system. In their normal function, these cells translate mechanical cues into signals that are necessary to renew the tissues, e.g., by continuously rebuilding the extracellular matrix being subjected to mechanical stress. In the presence of tissue insults (e.g., ischemia), inflammatory cues, or modifiable/unmodifiable risk conditions, these mechanical signals may be ‘misinterpreted’ by cardiac fibroblasts, giving rise to pathology programming. In fact, these cells are subject to changing their phenotype from that of matrix renewing to that of matrix scarring cells—the so-called myo-fibroblasts—involved in cardiac fibrosis. The links between alterations in the abilities of cardiac fibroblasts to ‘sense’ mechanical cues and molecular pathology programming are still under investigation. On the other hand, various evidence suggests that cell mechanics may control stromal cells phenotype by modifying the epigenetic landscape, and this involves specific non-coding RNAs. In the present contribution, we will provide examples in support of this more integrated vision of cardiac fibrotic progression based on the decryption of mechanical cues in the context of epigenetic and non-coding RNA biology.

Keywords: mechanotransduction; cardiac fibrosis; epigenetics; non-coding RNAs; cardiac fibroblast; heart failure

1. Introduction: Relevance of Cell Mechanics in Cardiac Fibrosis

Assessment of the mechanically dependent molecular machinery has become a new, insightful approach to deciphering cellular dynamics inside tissues, with implications in morphogenesis, tissue renewal, and pathology progression. For example, mechanically dependent coordination of tissue growth is recognized as a major determinant, either in pre-implantation or post-implantation embryonic patterning [1], as well as in cellular pathologic evolutions, such as in cancer [2]. Moreover, progenitor cell differentiation has been directly linked to compliance of the extracellular matrix (ECM) [3] and to geometry-dependent intracellular traction forces transmitted through the cytoskeleton to intracellular compartments, for example, the nucleus [4–8].

The heart is an organ undergoing continuous motion, with more than three billion contraction cycles during the average human life span. In a healthy myocardium, ECM turnover is under continuous renewal by the stromal component of the myocardium, composed of cardiac fibroblasts...
(CFs). Under conditions promoting metabolic alterations (e.g., hyperglycemia), inflammations such as chronic myocardial ischemia, or pressure overload, cardiac fibroblasts proliferate and evolve into profibrotic cells (so-called myofibroblasts (myoFs)), which contribute to consistent extracellular matrix deposition (prevalently, collagen I and III) and promote myocardial stiffening [9,10]. As a consequence, the Young’s elastic modulus increases up to ten times, ranging from 10–20 kPa in the physiological tissue to 50–200 kPa in the pathological tissue [11].

Other than being connected to pathological activation, cardiac matrix mechanics is relevant for controlling cardiomyocytes division and maturation. For example, it has been suggested that the beginning of the embryonic myocytes beating could be related to perturbations of mechanosensitive Ca2+ channels, determined by the progressive increase in matrix stiffness surrounding the cardiac progenitors before the onset of electromechanical coupling [12–14]. Additionally, the increase in mechanical load occurring at birth determines the maturation of the cardiac myocytes (CMs) contractile apparatus [15], causing further stiffening of the myocardium and mitotic block [16,17]. Furthermore, it has been shown that until two days after birth, mammalian hearts might regenerate by a mechanism involving (re)activation of the CMs division [18], and results obtained by treating neonatal mice with drugs able to ‘soften’ the myocardial matrix showed that the temporal window of heart regeneration can be experimentally prolonged [19]. In keeping with these findings, mammalian cardiomyocytes can be induced to back-differentiate and reactivate cell cycles by low-stiffness substrates [20], and cardiac regeneration in lower vertebrates (e.g., zebrafish) is accompanied by a transient softening of the extracellular matrix [21].

The responses of cells to mechanical cues have emerged as a general component of the chronic evolution of cardiovascular diseases and aging [22], a process with an important epigenetic component [23]. Taken together, these data suggest a tight relationship between the mechanosensitivity of CFs and downstream profibrotic cell signaling. This indicates a novel way to address myocardial fibrosis and to regulate the proliferation/maturation of the contractile cells, based on targeting cell mechanosensation-related effectors.

2. Alterations in Myocardial Compliance and Progression of Cardiac Fibrosis: Epigenetics Aspects

Epigenetics encompasses a series of mitotically and meiotically transmissible DNA/chromatin modifications independent of changes in the primary DNA sequence [24]. Epigenetics exerts its control of the genome functions through different covalent modifications of the chromatin, consisting of DNA methylation and histone modifications, as well as by interactions with non-coding RNA. These modifications affect the topology of the chromatin and, consequently, the accessibility of DNA to factors facilitating transcription initiation and elongation, DNA replication, recombination, and repair. We direct readers to specialized review articles on the types and the overall gene regulatory effects of DNA/chromatin epigenetic modifications in cardiovascular diseases [25]. It will be sufficient here to mention the following concepts.

(i) DNA methylation is defined by the covalent binding of a methyl group to the 5′ carbon of cytosine and is usually associated with gene expression repression, as it can decrease the accessibility of chromatin to DNA-binding proteins or transcription factors that are required for gene transcriptional activation [26].

(ii) Histones, the structural component of the chromatin, represent a target of several post-translational modifications, mainly occurring on amino acid residues of the N-terminal tails that protrude from the chromatin fibers [27]. Among these, acetylation promotes the relaxation of the chromatin structure associated with gene expression activation [28], while hypoacetylation and methylation promote chromatin condensation, resulting in gene expression repression [29].

As discussed in other contributions, epigenetic modifications can affect global gene expression by setting cellular ‘memories’ that reflect onto altered phenotypes and permanent diseased states. In the cardiovascular scenario, this appears particularly important, given the chronical nature of the disease
and its main metabolic basis [30]. Similar to metabolism-dependent memories, mechanical cues can also set permanent variations in cell functions, with possible consequences for chronic pathological programming. For example, it was found that cells embedded in three-dimensional hydrogels with high mechanical compliance are in a permanent activation state, even after shifting them to media with lower stiffness [31]. Importantly, the cells cultured in high stiffness media exhibit high levels of mechanically activated YAP/TAZ complex activity (see below) and the expression of pro-calcific master transcription factor RUNX-1, thus suggesting that activation of profibrotic/pro-calcific pathways can be permanently established by exposing cells to contacts with an extracellular matrix with high mechanical compliance. Since subjecting cells to mechanical constraints determines reversible nuclear shuttling of mechanically dependent transcription factors [7] and changes in the epigenetic landscape [24], it is possible that metabolic and mechanical cues cooperate in establishing a chronically activated phenotype that contributes to cardiac fibrosis [32–34].

While biochemical signals responsible for epigenetic alterations occurring in fibroblast activation are well described, the effect of mechanotransduction on the epigenetic set-up underlying transition from quiescent to activated myoFbs, and vice versa, is still under investigation [35]. On the other hand, some examples of pathways potentially involved in the epigenetic setting of myo-fibroblasts activations have been already provided, as follows.

Peroxisome proliferator-activated receptor (PPARα-δ and PPARα-γ) is a nuclear transcription factor highly expressed in the heart, with anti-inflammatory and anti-proliferative properties [36]. Diep and colleagues, using an animal model of cardiac hypertrophy, demonstrated that the treatment with PPARα ligand activator (fenofibrate) is able to prevent the progression of cardiac fibrosis [37]. Interestingly, in vitro experiments showed that the administration of PPARγ ligand resulted in a decrease in the collagen synthesis by angiotensin II-stimulated cardiac fibroblasts [38]. Although the molecular mechanism responsible for the PPARs anti-fibrotic effect remains unknown, growing evidence supports the involvement of epigenetics. In particular, the Methyl CpG binding protein (MeCP2), which binds methylated DNA [39], targets the 5′ end of the PPARγ gene promoter, silencing its transcription, and thus promotes fibroblast differentiation into myofibroblast [40], with consequences such as stiffening of the myocardial matrix.

Recent studies have shown that nuclear shape and stiffness controls gene expression and drives cell differentiation by exposing chromatin to mechanical cues and possible direct/indirect reshuffling of transcriptional accessibility [41]. These forces originate from tension forces of the cytoskeleton, namely, the actomyosin stress fibers, which transfer tensile forces from focal adhesions firmly attaching cells to stiff substrates in the nucleus through the Linker of Nucleoskeleton and Cytoskeleton (LINC) complex, nuclear lamins, and, finally, chromatin. As a result, the chromatin stretches and its accessibility to RNA polymerase II changes. Growing evidence supports the hypothesis that myofibroblast pathological activation is influenced by a convergence of mechanical stimuli transduced in the nucleus by the cytoskeleton, resulting in activation of profibrotic signaling [42]. For example, Alisafaei and colleagues used a mechanically dependent model of transcription and epigenetic factors (HDAC3, MKL) nucleocytoplasmic shuttling to investigate the actomyosin-dependent translocation in the nucleus of NIH 3T3 mice fibroblast cells. Results showed that cells placed on smaller substrate areas decreased nuclear volumes and increased histone acetylation levels, and that the reduction of actomyosin contractility caused a nuclear translocation of histone deacetylase 3 (HDAC3). Once reaching the nucleus, HDAC3 exerted its function, reducing the histone acetylation level and resulting in chromatin compaction and reduction of nuclear volume. In order to investigate the association between alterations in actomyosin contractility and HDAC3 shuttling from the cytoplasm to the nucleus, where it is responsible for chromatin condensation, Jain and colleagues studied treated NIH 3T3 mice fibroblasts with inhibitors of the actomyosin fibers contractility (e.g., Blebblistatin and Y27632) [43]. The administration of these drugs favored degradation of the nuclear factor IκB-α (which normally sequesters HDAC3 in the cytoplasm), releasing the acetylating enzyme that translocates into the nucleus. Taken together, these data suggest a correlation between the actomyosin contractility
and the nucleocytoplasmic translocation of the epigenetic factors on substrates with different shapes and areas. This interplay between mechanical forces and epigenetics may greatly contribute in the activation/silencing of profibrotic pathways, establishing a direct link between mechanosensation and permanent epigenetic changes (Figure 1).

**Figure 1.** Activation of cardiac fibroblasts (CFs) involves mechanosensing and is related to variations in epigenetic programming and specific non-coding (ncRNAs). The panel illustrates the transition from normal conditions, characterized by a compliant matrix and a low level of cellular mechanical stress; to the pathologic programming occurring due to remodeling/crosslinking of the extracellular matrix (ECM); to the final stage of myo-fibroblast differentiation, which involves nuclear straining, nuclear translocation of mechanically dependent transcription factors, proliferation, and pro-inflammatory phenotypes.

The YAP/TAZ complex has been identified as the transcriptional component of the so-called hippo pathway, an intracellular signaling cascade involved in tissue growth and homeostasis [44]. It has...
been demonstrated that transmission of mechanical forces to the nucleus from the cytoskeleton via the LINC complex determines YAP/TAZ translocation through the nuclear pores [6]. The involvement of YAP signaling in fibrotic processes has been demonstrated with the finding that human cardiac fibroblasts exposed to cyclic straining determines YAP nuclear translocation and activation of cell cycle genes (Figure 2) [44]. In addition, in a mouse model of myocardial infarction, it was demonstrated that YAP/TAZ is abundantly expressed in cells located juxtaposed to the infarct border zone, suggesting a direct role in control of collagen deposition and thus in ECM stiffening [45]. Moreover, the stiffening of the matrix as a consequence of myofibroblast activity mechanoactivates YAP, which positively regulates the production of profibrotic mediators and ECM proteins, resulting in a feed-forward loop of fibroblast activation and tissue fibrosis [46]. Since YAP functions are controlled by post-translational modifications such as acetylation [47], and are subject to metabolic and nutrient control [48,49]; these data establish a possible convergence between metabolic control of epigenetics and CF mechanics in cardiac fibrosis.

Other pathways, such as those related to cellular redox control, may represent potent pathological activators connected to cell mechanics in cardiac fibrosis. In this respect, Hata and colleagues observed that treating HeLa cells with agents that damaged the DNA and formed methylated bases with cytotoxic properties (alkylating agents, e.g., methyl methanesulfonate, cisplatin, doxorubicin, and N-methyl-N-nitrosourea) determined YAP translocation and decreased phosphorylation levels. Once in the nucleus, nuclear acetyltransferases cardiopulmonary bypass (CBP) targeted YAP at Lys-494 and Lys-497, determining its transcriptional activation [50]. Although a similar mechanism has not yet been demonstrated in CFs, this evidence suggests synergism between the epigenetic post-translational modification pathway and the regulation of the transcriptional component of the hippo pathway, which depends on the balance between the cytoplasmic and the nuclear-localized YAP, thus reinforcing mechanical signaling by shifting the balance in favor of nuclear translocation and activation of profibrotic genes.

Inflammation is involved in cardiac fibrosis progression at multiple levels, from the response to acute/chronic damages (e.g., ischemia and pressure overload) to the chronic setting of fibrosis, mainly consisting of collagen deposition. During the first phase after myocardial damage, the release of pro-inflammatory mediators recruits inflammatory cells, such as neutrophils and monocytes, into the myocardium and activates myocardial-resident fibroblasts [51]. Although there is no evidence of cooperation between mechanosensing-activated pathways and epigenetic circuitries in the recruitment and pro-inflammatory activities of innate immunity cells, it is important to highlight that functional cooperativity between inflammatory cells (e.g., macrophages) and fibroblasts has been recently described with the demonstration that deformations in collagen matrices produced by fibroblasts are directly involved in macrophage migration [52]. This suggests that epigenetic alterations of the fibroblasts’ activity, such as those observed in cardiac fibrosis, may supervise inflammatory cells’ recruitment by long-range mechanical signaling spread over the extracellular matrix of the damaged myocardium.

During the relapse phase of the inflammatory process, a clearer relationship may exist between epigenetics CFs mechanics and fibrosis through the effects of the transforming growth factor-beta (TGF-β), the downstream signal transducers (Smads), and transcriptional coactivators p300/CBP in collagen-I synthesis [53]. Upon their receptor-induced activation promoted by TGF-β, Smad2 and Smad3 oligomerize with Smad4 and translocate into the nucleus to regulate the expression of several profibrotic genes. This transcriptional activity is further enhanced by co-activator p300/CBP, which bounds and acetylates Smad2 and Smad3 (Figure 2) [54]. Since the mechanically dependent transcription factor complex YAP/TAZ has been found to cooperate with transcriptional components of the TGF-β pathway [47,55], these data, together, add a novel level of complexity to epigenetic control of cardiac fibrosis through the activity of transcriptional complexes, with histone acetylation activity directly connected to fibrotic paracrine signaling.
The principal ncRNAs involved in the cardiac fibrotic process are listed in Table 1. Non-coding RNAs (ncRNAs) are RNA species transcribed but not translated into proteins. There are two different categories of ncRNA, depending on size: (1) small non-coding RNAs (<200 bp), including microRNAs (miRNA) and PIWI-interacting RNAs (piRNA); and (2) long non-coding RNAs (lncRNAs, >200 bp), including long intergenic non-coding RNA (lincRNA), circular RNA (circRNAs), natural antisense transcripts (NATs), and enhancer RNAs (eRNAs) [57]. For a complete description including microRNAs (miRNA) and PIWI-interacting RNAs (piRNA); and (2) long non-coding RNAs (lncRNAs, >200 bp), including long intergenic non-coding RNA (lincRNA), circular RNA (circRNAs), natural antisense transcripts (NATs), and enhancer RNAs (eRNAs) [57]. For a complete description of the ncRNAs’ biology in the context of cardiovascular disease, we redirect to a companion article to this report [58]. The principal ncRNAs involved in the cardiac firotic process are listed in Table 1.

### Table 1. Non-coding (ncRNAs) with implications in cardiac fibrosis.

| NcRNA | Target Gene | Pro- or Anti-Fibrotic | References |
|-------|-------------|-----------------------|------------|
| miR-18| CTGF        | Anti                  | [59]       |
| miR-19| CTGF        | Anti                  | [59]       |
| miR-21| PTEN, SMAD7, STAT3, PPAR-α | Pro | [60]       |
|       | COL1A1, 1A2, 4A5, FBN, ELN1, PDGFR, TAB1, ADAM | Anti | [61]       |
| miR-29| PPAR-α      | Pro                   | [62]       |
Table 1. Cont.

| NcRNA          | Target Gene | Pro- or Anti-Fibrotic | References |
|----------------|-------------|-----------------------|------------|
| miR-133        | CTGF        | Anti                  | [63]       |
| miR-15         | TGF-β, SMAD7, SMAD3 | Anti                  | [63]       |
| miR-30c        | CTGF        | Anti                  | [63]       |
| miR-101        | TGF-β       | Anti                  | [64]       |
| miR-34         | SMAD4       | Pro                   | [65]       |
| miR-212        | FoxO3       | Pro                   | [66]       |
| miR-199b       | Dyrk1A      | Pro                   | [67]       |
| miR-150        | PTX3        | Pro                   | [68]       |
| miR-155        | SMAD4, SMA2, RhoA | Pro                  | [69]       |
| LncRNA-Meg3    | MMP2        | Pro                   | [70]       |
| LncRNA-Wisper  | Col3a2, Fn1 | Pro                   | [71]       |
| LncRNA-Miat    | miR-29, miR-30, and miR-133 | Pro               | [72]       |
| LncRNA-Malat1  | TGFBR2, SMAD3 | Pro                 | [73]       |
| LncRNA-PRL     | mir-Let7d   | Pro                   | [74]       |
| LncRNA-H19     | DUSP5, ERK1 | Pro                   | [61]       |
| LncRNA-n379519 | miR-30      | Pro                   | [75]       |
| LncRNA-NR024118 | AT1       | Pro                   | [76]       |

To date, several studies demonstrate the involvement of ncRNAs in fibrosis, with potential clinical implications as biomarkers and therapeutic targets. Piccoli and colleagues performed a lncRNA analysis in mice CFs and identified more than 1400 lncRNAs that were deregulated in hypertrophic mice hearts. Among these, CF-specific lncRNA maternally expressed that gene 3 (Meg3) was upregulated [70]. Meg-3 is a conserved chromatin-associated lncRNA that transcriptionally controls the activity of p53 in the promoter regions of MMP-2 and is expressed by CFs. Moreover, it has been reported that MMP-2 is transcriptionally induced by the well-known fibrogenic factor TGF-β. The direct interaction between Meg-3 and p53 activates matrix metalloproteinase-2 (MMP-2), affecting the composition of the ECM. Modification of the cardiac matrix is linked to variations in its mechanical characteristics, which represents further stimuli for the activation of cardiac fibroblasts and fibrosis progression.

An important mechanism involved in the role of miRNAs in cardiac fibrosis has been found from the discovery that several miRNAs are dysregulated in myocardial injury models. One of them, miR-29, was found downregulated in infarcted hearts, with the consequent elevation of profibrotic proteins expression, including collagens [77]. This finding is in line with observations showing a lower expression of the miRNA in fibrosis-related diseases [61], clearly indicating a potential role of miR-29 as a ‘cardioprotector’. On the other hand, compelling evidence shows that expression of miR-29 is under the control of mechanotransduction pathways, and in particular by the YAP/TEAD transcriptional complex through consensus binding sequences for YAP/TEAD in the promoters of the microRNAs-29a/b/c gene variants, thus producing apparently contradictory results. At the moment, it is not possible to conclude whether or not the ischemia-related downregulation of miR-29 is the only signal promoting cardiac fibrosis in the context of cardiac stiffening. In this regard, it has to be noted that overexpression of miR-29 in fibroblasts has led to only a partial inhibition of collagens expression [77], and that variations in viscoelastic properties of the 3D matrix have stiffness-independent effects on the machinery responsible for miRNA biogenesis [78], thus reconciling the role of YAP as a positive regulator of miR-29 with antifibrotic activity of the miR (Figure 1).

As introduced in the previous section, cells appear to keep a memory of cumulative exposure to mechanical cues, with possible interplay of permanent modifications of the epigenetic landscape [31]. Additionally, ncRNA expression in fibrotic cells may take part in mechanical memory. For example, in mesenchymal cells (MSCs), miR-21 has been identified as a long-term memory keeper of the fibrogenic program [60]. As demonstrated in a study with rats MSCs cultured on gels with different stiffness, the stiffening of the ECM causes the upregulation of miR-21, which is in turn involved in the ECM deposition. The increase in miR-21 expression during stiff-priming depended on the regulation exerted
by acutely mechanosensitive myocardin-related transcription factor-A (MRTF-A/MLK-1) and was maintained over two weeks after the removal of mechanical cues. Moreover, silencing miR-21 at the end of stiff-priming resulted in a loss of mechanical memory and the re-acquisition of cellular sensibility into soft matrices [60]. Since MRTF is translocated in the nucleus in response to cell straining [79] and miR-21 is a part of the fibrotic process under the control of TGF-β [56], this evidence establishes a direct link between cell mechanosensing and the ncRNA regulation of cardiac fibrosis (Figure 1).

Recently, a study carried out on mice fibroblasts described a pattern of miRNAs able to exert control on the mechanical properties of cells and tissues [80]. Once they identified the interaction between miRNAs and mRNA, results showed 127 mRNAs. Seventy-three of these specifically encoded a group of proteins called contractility adhesion matrix proteins (CAM). Remarkably, the post-transcriptional regulation of these proteins depended on substrate stiffness and thus on cell mechanics. In order to investigate this regulation, the authors seeded endothelial cells lacking Argonaute2 (AGO2) or DROSHA, two proteins involved in miRNA maturation [72], on substrates with different stiffness. Results showed that, while in control cells, the contractility increased only in high levels of stiffness. In mutant cells, this occurred also on softer substrates. Interestingly, the mutant population exhibited cell area, contractility, and YAP nuclear localization significantly higher compared to controls, thus demonstrating that miRNA biogenesis is necessary for the discrimination between physiologic and non-physiologic cell mechanics.

A further lncRNA emerging for its involvement in fibrosis is the myocardial infarction associated transcript (MIAT) [81], whose expression was reported to be higher in association with cardiac fibrosis in a mouse model of myocardial infarction. As a result of MIAT knockdown, fibrosis was reduced, with a decrease in collagen deposition and inhibition of fibroblasts proliferation. Moreover, cardiac functions improved, with a restoring of physiological levels of fibrosis-related effectors [72].

Finally, there is evidence that the connective tissue growth factor (CTGF), a crucial player in fibrosis onset, is post-transcriptionally controlled by miR-133 and miR-30, which interact directly with the 3’ untranslated region of CTGF. In particular, the expression of both miRNAs is inversely related to the levels of CTGF, and their knockdown resulted in an increase of the CTGF amount in mice fibroblasts. Moreover, overexpression of miR-133 or miR-30 reduced CTGF levels and subsequent collagen synthesis [63]. Since CTGF is a canonical target of the YAP/TAZ complex, this constitutes an interesting example of a potential feedback loop for mechanosensing-dependent control of fibrosis in the heart. Almen and colleagues unraveled a similar regulatory role of miR-18/19 in CTGF; the expression of these miRs, indeed, resulted in a decrease of collagen type I and III depositions [59].

4. Conclusions

In the present report, we highlight the possible interplay of mechanotransduction pathways with epigenetic and ncRNAs in the control of gene expression in heart fibrosis. Cell-based mechanosensing, indeed, has a significant impact on a variety of cellular functions, from embryonic stages to tissue aging and remodeling, and it has a potential to interact on a multilevel and multiscale modality with classical paracrine and metabolic and inflammatory pathways, thus connecting cellular disease memories with tissue architecture and remodeling. While in cancer pathophysiology these concepts are better established and demonstrated, in the cardiovascular diseases scenario, these relationships are only starting to be discovered. We believe that a deeper understanding of these aspects, using interdisciplinary research approaches, will contribute to resolving the molecular setting of cardiac fibrosis and devising therapeutic strategies to combat the increasing burden of heart failure.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Bredov, D.; Volodyaev, I. Increasing complexity: Mechanical guidance and feedback loops as a basis for self-organization in morphogenesis. BioSystems 2018, 173, 133–156. [CrossRef]
2. Papalazarou, V.; Salmeron-Sanchez, M.; Machesky, L.M. Tissue engineering the cancer microenvironment-challenges and opportunities. Biophys. Rev. 2018, 10, 1695–1711. [CrossRef]

3. Engler, A.J.; Sen, S.; Sweeney, H.L.; Discher, D.E. Matrix elasticity directs stem cell lineage specification. Cell 2006, 126, 677–689. [CrossRef]

4. McBeath, R.; Pirones, D.M.; Nelson, C.M.; Bhadriraju, K.; Chen, C.S. Cell shape, cytoskeletal tension, and RhoA regulate stem cell lineage commitment. Dev. Cell 2004, 6, 483–495. [CrossRef]

5. Nelson, C.M.; Jean, R.P.; Tan, J.L.; Liu, W.F.; Sniadecki, N.J.; Specter, A.A.; Chen, C.S. Emergent patterns of growth controlled by multicellular form and mechanics. Proc. Natl. Acad. Sci. USA 2005, 102, 11594–11599. [CrossRef]

6. Elosegui-Artola, A.; Andreu, I.; Beedle, A.E.M.; Lezamiz, A.; Uroz, M.; Kosmalska, A.J.; Oria, R.; Kechagia, J.Z.; Rico-Lastres, P.; Le Roux, A.L.; et al. Force Triggers YAP Nuclear Entry by Regulating Transport across Nuclear Pores. Cell 2017, 171, 1397–1410 e1314. [CrossRef]

7. Lomakin, A.; Nader, G.; Piel, M. Forcing Entry into the Nucleus. Dev. Cell 2017, 43, 547–548. [CrossRef]

8. Elosegui-Artola, A.; Oria, R.; Chen, Y.; Kosmalska, A.; Perez-Gonzalez, C.; Castro, N.; Zhu, C.; Trepat, X.; Rosa-Cusachs, P. Mechanical regulation of a molecular clutch defines force transmission and transduction in response to matrix rigidity. Nat. Cell Biol. 2016, 18, 540–548. [CrossRef]

9. Schroer, A.K.; Merryman, W.D. Mechanobiology of myofibroblast adhesion in fibrotic cardiac disease. J. Cell Sci. 2015, 128, 1865–1875. [CrossRef]

10. Tallquist, M.D.; Molkentin, J.D. Redefining the identity of cardiac fibroblasts. Nat. Rev. Cardiol. 2017, 14, 484–491. [CrossRef]

11. van Putten, S.; Shafieyan, Y.; Hinz, B. Mechanical control of cardiac myofibroblasts. J. Mol. Cell. Cardiol. 2016, 93, 133–142. [CrossRef] [PubMed]

12. Chion, K.K.; Rocks, J.W.; Chen, C.Y.; Cho, S.; Merkus, K.E.; Rajaratnam, A.; Robison, P.; Tewari, M.; Vogel, K.; Majkut, S.F.; et al. Mechanical signaling coordinates the embryonic heartbeat. Proc. Natl. Acad. Sci. USA. 2016, 113, 8939–8944. [CrossRef] [PubMed]

13. Majkut, S.; Idema, T.; Swift, J.; Krieger, C.; Liu, A.; Discher, D.E. Heart-specific stiffening in early embryos parallels matrix and myosin expression to optimize beating. Curr. Biol. CB 2013, 23, 2434–2439. [CrossRef] [PubMed]

14. Majkut, S.; Dingal, P.C.; Discher, D.E. Stress sensitivity and mechanotransduction during heart development. Curr. Biol. CB 2014, 24, R495–R501. [CrossRef] [PubMed]

15. Pandey, P.; Hawkes, W.; Hu, J.; Megone, W.V.; Gautrot, J.; Anilkumar, N.; Zhang, M.; Hirvonen, L.; Cox, S.; Ehler, E.; et al. Cardiomyocytes Sense Matrix Rigidity through a Combination of Muscle and Non-muscle Myosin Contractions. Dev. Cell 2018, 45, 661. [CrossRef]

16. Ebler, E. Cardiac cytoarchitecture-why the “hardware” is important for heart function! Biochim. et Biophys. Acta 2016, 1863, 1857–1863. [CrossRef]

17. Kennedy-Lydon, T.; Rosenthal, N. Cardiac regeneration: All work and no repair? Sci. Transl. Med. 2017, 9. [CrossRef]

18. Porrello, E.R.; Mahmoud, A.I.; Simpson, E.; Hill, J.A.; Richardson, J.A.; Olson, E.N.; Sadek, H.A. Transient regenerative potential of the neonatal mouse heart. Science 2011, 331, 1078–1080. [CrossRef]

19. Notari, M.; Ventura-Rubio, A.; Bedford-Guaus, S.J.; Jorba, I.; Mulero, L.; Navajas, D.; Marti, M.; Raya, A. The local microenvironment limits the regenerative potential of the mouse neonatal heart. Sci. Adv. 2018, 4, eaa0553. [CrossRef]

20. Yahalom-Ronen, Y.; Rajchman, D.; Sarig, R.; Geiger, B.; Tzahor, E. Reduced matrix rigidity promotes neonatal cardiomyocyte dedifferentiation, proliferation and clonal expansion. eLife 2015, 4. [CrossRef]

21. Yu, J.K.; Sarathchandra, P.; Chester, A.; Yacoub, M.; Brand, T.; Butler, J.T. Cardiac regeneration following cryoinjury in the adult zebrafish targets a maturation-specific biomechanical remodeling program. Sci. Rep. 2018, 8, 15661. [CrossRef]

22. Garoffolo, G.; Pesce, M. Mechanotransduction in the Cardiovascular System: From Developmental Origins to Homeostasis and Pathology. Cells 2019, 8. [CrossRef]

23. Vinci, M.C.; Polvani, G.; Pesce, M. Epigenetic programming and risk: The birthplace of cardiovascular disease? Stem Cell Res. 2013, 9, 241–253. [CrossRef]

24. Lv, L.; Tang, Y.; Zhang, P.; Liu, Y.; Bai, X.; Zhou, Y. Biomaterial Cues Regulate Epigenetic State and Cell Functions-A Systematic Review. Tissue Eng. Part B Rev. 2018, 24, 112–132. [CrossRef]
25. Zhang, W.; Song, M.; Qu, J.; Liu, G.H. Epigenetic Modifications in Cardiovascular Aging and Diseases. *Circ. Res.* 2018, 123, 773–786. [CrossRef]

26. van der Harst, P.; de Windt, L.J.; Chambers, J.C. Translational Perspective on Epigenetics in Cardiovascular Disease. *J. Am. Coll. Cardiol.* 2017, 70, 590–606. [CrossRef]

27. Natsume-Kitatani, Y.; Shiga, M.; Mamitsuka, H. Genome-wide integration on transcription factors, histone acetylation and gene expression reveals genes co-regulated by histone modification patterns. *PLoS ONE* 2011, 6, e22281. [CrossRef]

28. Talbert, P.B.; Henikoff, S. Spreading of silent chromatin: Inaction at a distance. *Nat. Rev. Genet.* 2006, 7, 793–803. [CrossRef]

29. Richards, E.J.; Elgin, S.C. Epigenetic codes for heterochromatin formation and silencing: Rounding up the usual suspects. *Cell* 2002, 108, 489–500. [CrossRef]

30. Costantino, S.; Ambrosini, S.; Paneni, F. The epigenetic landscape in the cardiovascular complications of diabetes. *J. Endocrinol. Investig.* 2019, 42, 505–511. [CrossRef]

31. Yang, C.; Tibbitt, M.W.; Basta, L.; Anseth, K.S. Mechanical memory and dosing influence stem cell fate. *Nat. Mater.* 2014, 13, 645–652. [CrossRef] [PubMed]

32. Prasher, D.; Greenway, S.C.; Singh, R.B. The impact of epigenetics on cardiovascular disease. *Biochem. Cell Biol. Biochim. et Biol. Cell.* 2019, 1–11. [CrossRef] [PubMed]

33. Bechtel, W.; McGoohan, S.; Zeisberg, E.M.; Muller, G.A.; Kalbacher, H.; Salant, D.J.; Muller, C.A.; Kalluri, R.; Zeisberg, M. Methylation determines fibroblast activation and fibrogenesis in the kidney. *Nat. Med.* 2010, 16, 544–550. [CrossRef] [PubMed]

34. Vineis, P.; Chatziioannou, A.; Cunilffe, V.T.; Flanagan, J.M.; Hanson, M.; Kirsch-Volders, M.; Kyrtopoulos, S. Epigenetic memory in response to environmental stressors. *FASEB J.* 2017, 31, 2241–2251. [CrossRef]

35. Page, A.; Mann, D.A.; Mann, J. The mechanisms of HSC activation and epigenetic regulation of HSCs phenotypes. *Curr. Pathobiol. Rep.* 2014, 2, 163–170. [CrossRef]

36. Kota, B.P.; Huang, T.H.; Roufogalis, B.D. An overview on biological mechanisms of PPARs. *Pharmacol. Res.* 2005, 51, 85–94. [CrossRef]

37. Diep, Q.N.; Benkirane, K.; Amiri, F.; Cohn, J.S.; Endemann, D.; Schiffin, E.L. PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. *J. Mol.Cell. Cardiol.* 2004, 36, 295–304. [CrossRef]

38. Chen, K.; Chen, J.; Li, D.; Zhang, X.; Mehta, J.L. Angiotensin II regulation of collagen type I expression in cardiac fibroblasts: Modulation by PPAR-gamma ligand pioglitazone. *Hypertension* 2004, 44, 655–661. [CrossRef]

39. Du, Q.; Luu, P.L.; Stirzaker, C.; Clark, S.J. Methyl-CpG-binding domain proteins: Readers of the epigenome. *Epigenomics* 2015, 7, 1051–1073. [CrossRef]

40. Mann, J.; Chu, D.C.; Maxwell, A.; Oakley, F.; Zhu, N.L.; Tsukamoto, H.; Mann, D.A. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. *Gastroenterology* 2010, 138, 705–714.e4. [CrossRef]

41. Tajik, A.; Zhang, Y.; Wei, F.; Sun, J.; Jia, Q.; Zhou, W.; Singh, R.; Khanna, N.; Belmont, A.S.; Wang, N. Transcription upregulation via force-induced direct stretching of chromatin. *Nat. Mater.* 2016, 15, 1287–1296. [CrossRef] [PubMed]

42. Herum, K.M.; Choppe, J.; Kumar, A.; Engler, A.J.; McCulloch, A.D. Mechanical regulation of cardiac fibroblast profibrotic phenotypes. *Mol. Biol. Cell.* 2017, 28, 1871–1882. [CrossRef] [PubMed]

43. Jain, N.; Iyer, K.V.; Kumar, A.; Shivashankar, G.V. Cell geometric constraints induce modular gene-expression patterns via redistribution of HDAC3 regulated by actomyosin contractility. *Proc. Natl. Acad. Sci. USA* 2013, 110, 11349–11354. [CrossRef] [PubMed]

44. Dupont, S.; Morsut, L.; Aragona, M.; Enzo, E.; Giuliani, S.; Cordenonsi, M.; Zanconato, F.; Le Digabel, J.; Forcato, M.; Bicciato, S.; et al. Role of YAP/TAZ in mechanotransduction. *Nature* 2011, 474, 179–183. [CrossRef] [PubMed]

45. Ugolini, G.S.; Rasponi, M.; Pavesi, A.; Santoro, R.; Kamm, R.; Fiore, G.B.; Pesce, M.; Soncini, M. On-chip assessment of human primary cardiac fibroblasts proliferative responses to uniaxial cyclic mechanical strain. *Biotechnol. Bioeng.* 2016, 113, 859–869. [CrossRef] [PubMed]
46. Mosquiera, D.; Pagliari, S.; Uto, K.; Ebara, M.; Romanasso, S.; Escobedo-Lucea, C.; Nakanishi, J.; Taniguchi, A.; Franzese, O.; Di Nardo, P.; et al. Hippo pathway effectors control cardiac progenitor cell fate by acting as dynamic sensors of substrate mechanics and nanostructure. ACS Nano 2014, 8, 2033–2047. [CrossRef] [PubMed]

47. Noguchi, S.; Saito, A.; Nagase, T. YAP/TAZ Signaling as a Molecular Link between Fibrosis and Cancer. Int. J. Mol. Sci. 2018, 19. [CrossRef]

48. Lin, Z.; Guo, H.; Cao, Y.; Zohrabian, S.; Zhou, P.; Ma, Q.; VanDusen, N.; Guo, Y.; Zhang, J.; Stevens, S.M.; et al. MicroRNA-21 preserves the fibrotic mechanical memory of mesenchymal stem cells. Nat. Mater. 2018, 17, 45–53. [CrossRef]

49. Santinon, G.; Pocaterra, A.; Dupont, S. Control of YAP/TAZ Activity by Metabolic and Nutrient-Sensing Pathways. Trends Cell Biol. 2016, 26, 289–299. [CrossRef] [PubMed]

50. Hata, S.; Hirayama, J.; Kajiho, H.; Nakagawa, K.; Hata, Y.; Katada, T.; Furutani-Seiki, M.; Nishina, H. A novel acetylation cycle of transcription co-activator Yes-associated protein that is downstream of Hippo pathway is triggered in response to SN2 alykating agents. J. Biol. Chem. 2012, 287, 22089–22098. [CrossRef] [PubMed]

51. Zhang, Y.; Bauersachs, J.; Langer, H.F. Immune mechanisms in heart failure. Eur. J. Heart Fail. 2017, 19, 1379–1389. [CrossRef] [PubMed]

52. Pakshir, P.; Alizadehgiashi, M.; Wong, B.; Coelho, N.M.; Chen, X.; Gong, Z.; Shenoy, V.B.; McCulloch, C.A.; Hinz, B. Dynamic fibroblast contractions attract remote macrophages in fibrillar collagen matrix. Nat. Commun. 2019, 10, 1850. [CrossRef]

53. Ghosh, A.K.; Yuan, W.; Mori, Y.; Varga, J. Smad-dependent stimulation of type I collagen gene expression in human skin fibroblasts by TGF-beta involves functional cooperation with p300/CBP transcriptional coactivators. Oncogene 2000, 19, 3546–3555. [CrossRef] [PubMed]

54. Tu, A.W.; Luo, K. Acetylation of Smad2 by the co-activator p300 regulates activin and transforming growth factor beta response. J. Biol. Chem. 2007, 282, 21187–21196. [CrossRef] [PubMed]

55. Greco, S.; Gaetano, C.; Martelli, F. Long Noncoding Competing Endogenous RNA Networks in Age-Associated Cardiovascular Diseases. Int. J. Mol. Sci. 2019, 20. [CrossRef] [PubMed]

56. duisters, R.F.; Tijsen, A.J.; Schroen, B.; Leenders, J.J.; Lentink, V.; van der Made, I.; Herias, V.; van Leeuwen, R.E.; et al. miR-133 and miR-30 regulate connective tissue growth factor: Implications of a role for microRNAs in myocardial matrix remodeling. Circ. Res. 2009, 104, 170–178, 176p following 178. [CrossRef] [PubMed]

57. Zhang, Y.; Luo, G.; Zhang, M.; Zhou, J.; Gao, W.; Xuan, X.; Yang, X.; Yang, D.; Tian, Z.; Ni, B.; et al. Critical effects of long non-coding RNA on fibrosis diseases. Exp. Mol. Med. 2018, 50, e428. [CrossRef]

58. Li, L.; Bounds, K.R.; Chatterjee, P.; Gupta, S. MicroRNA-130a, a Potential Antifibrotic Target in Cardiac Fibrosis. J. Am. Heart Assoc. 2017, 6. [CrossRef] [PubMed]

59. Pan, Z.; Sun, X.; Shan, H.; Wang, N.; Wang, J.; Ren, J.; Feng, S.; Xie, L.; Lu, C.; Yuan, Y.; et al. MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene/transforming growth factor-beta1 pathway. Circulation 2012, 126, 840–850. [CrossRef]

60. Bernardo, B.C.; Gao, X.M.; Winbanks, C.E.; Boey, E.J.; Tham, Y.K.; Kiriazis, H.; Gregorevic, P.; Obad, S.; Kauppinen, S.; Du, X.J.; et al. Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc. Natl. Acad. Sci. USA 2012, 109, 17615–17620. [CrossRef]
66. Ucar, A.; Gupta, S.K.; Fiedler, J.; Eriksi, E.; Kardasinski, M.; Batkai, S.; Dangwal, S.; Kumarswamy, R.; Bang, C.; Holzmann, A.; et al. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. *Nat. Commun.* 2012, 3, 1078. [CrossRef]

67. da Costa Martins, P.A.; Salic, K.; Gladka, M.M.; Armand, A.S.; Leptidis, S.; el Azzouzi, H.; Hansen, A.; Coenen-de Roo, C.J.; Bierhuizen, M.F.; van der Nagel, R.; et al. MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling. *Nat. Cell Biol.* 2010, 12, 1220–1227. [CrossRef]

68. Shen, J.; Xing, W.; Gong, F.; Wang, W.; Yan, Y.; Zhang, Y.; Xie, C.; Fu, S. MiR-150-5p retards the progression of myocardial fibrosis by targeting EGR1. *Cell Cycle* 2019, 18, 1335–1348. [CrossRef]

69. Faraoni, I.; Antonetti, F.R.; Cardone, J.; Bonmassar, E. miR-155 gene: A typical multifunctional microRNA. *Biochim. et Biophys. Acta* 2009, 1792, 497–505. [CrossRef]

70. Piccoli, M.T.; Gupta, S.K.; Viereck, J.; Foinquinos, A.; Samolovac, S.; Kramer, F.L.; Garg, A.; Remke, J.; Zimmer, K.; Batkai, S.; et al. Inhibition of the Cardiac Fibroblast-Enriched IncRNA Meg3 Prevents Cardiac Fibrosis and Diastolic Dysfunction. *Circ. Res.* 2017, 121, 575–583. [CrossRef]

71. Samak, M.; Fatullahayev, J.; Bashabnikov, A.; Zeriouh, M.; Schmack, B.; Farag, M.; Popov, A.F.; Dohmen, P.M.; Choi, Y.H.; Wahlers, T.; et al. Cardiac Hypertrophy: An Introduction to Molecular and Cellular Basis. *Med Sci. Monit. Basic Res.* 2016, 22, 75–79. [CrossRef] [PubMed]

72. Qu, X.; Du, Y.; Shu, Y.; Gao, M.; Sun, F.; Luo, S.; Yang, T.; Zhan, L.; Yuan, Y.; Chu, W.; et al. MIAT Is a Pro-fibrotic Long Non-coding RNA Governing Cardiac Fibrosis in Post-infarct Myocardium. *Sci. Rep.* 2017, 7, 42657. [CrossRef] [PubMed]

73. Huang, S.; Zhang, L.; Song, J.; Wang, Z.; Huang, X.; Guo, Z.; Chen, F.; Zhao, X. Long noncoding RNA MALAT1 mediates cardiac fibrosis in experimental postinfarct myocardium mice model. *J. Cell. Physiol.* 2019, 234, 2997–3006. [CrossRef] [PubMed]

74. Liang, H.; Pan, Z.; Zhao, X.; Liu, L.; Sun, J.; Su, X.; Xu, C.; Zhou, Y.; Zhao, D.; Xu, B.; et al. LncRNA PFL contributes to cardiac fibrosis by acting as a competing endogenous RNA of let-7d. *Theranostics* 2018, 8, 1180–1194. [CrossRef]

75. Chen, C.; Zhou, L.; Wang, H.; Chen, J.; Li, W.; Liu, W.; Shen, M.; Liu, H.; Fu, X. Long noncoding RNA CNALPTC1 promotes cell proliferation and migration of papillary thyroid cancer via sponging miR-30 family. *Am. J. Cancer Res.* 2018, 8, 192–206.

76. Jiang, X.; Zhang, F.; Ning, Q. Losartan reverses the down-expression of long noncoding RNA-NR024118 and Cdkn1c induced by angiotensin II in adult rat cardiac fibroblasts. *Pathol. Biol.* 2015, 63, 122–125. [CrossRef]

77. van Rooij, E.; Sutherland, L.B.; Thatcher, J.E.; DiMaio, J.M.; Naseem, R.H.; Marshall, W.S.; Hill, J.A.; Olson, E.N. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. *Proc. Natl. Acad. Sci. USA* 2008, 105, 13027–13032. [CrossRef]

78. Herrera, J.; Beisang, D.J.; Peterson, M.; Forster, C.; Gilbertsen, A.; Benyumov, A.; Smith, K.; Korenczuk, C.E.; Barocas, V.H.; Guenther, K.; et al. Dicer1 Deficiency in the Idiopathic Pulmonary Fibrosis Fibroblastic Focus Promotes Fibrosis by Suppressing MicroRNA Biogenesis. *Am. J. Respir. Crit. Care Med.* 2018, 198, 486–496. [CrossRef]

79. Foster, C.T.; Gualdrini, F.; Treisman, R. Mutual dependence of the MRTF-SRF and YAP-TEAD pathways in cancer-associated fibroblasts is indirect and mediated by cytoskeletal dynamics. *Genes Dev.* 2017, 31, 2361–2375. [CrossRef]

80. D’Angelo, A.; Goddeau, A.L.; Solon, J. A New Player in Tissue Mechanics: MicroRNA Control of Mechanical Homeostasis. *Dev. Cell* 2019, 48, 596–598. [CrossRef]

81. Ishii, N.; Ozaki, K.; Sato, H.; Mizuno, H.; Saito, S.; Takahashi, A.; Miyamoto, Y.; Ikegawa, S.; Kamatani, N.; Hori, M.; et al. Identification of a novel non-coding RNA, MIAT, that confers risk of myocardial infarction. *J. Hum. Genet.* 2006, 51, 1087–1099. [CrossRef] [PubMed]